Evidence map›Paper›PMID 38956379›Full record

ArticleNature immunology2024

Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping.

Herman Netskar, Aline Pfefferle, Jodie P Goodridge, Ebba Sohlberg, Olli Dufva, Sarah A Teichmann, Demi Brownlie, Jakob Michaëlsson, Nicole Marquardt, Trevor Clancy and 2 more

Abstract read
In one paragraph

Article in Nature immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Cellular immunotherapy in melanoma: the next frontier in cancer treatment.Journal of experimental & clinical cancer research : CR · 2026
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Herman Netskar *Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-3081-9581
Aline Pfefferle *Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. aline.pfefferle@ki.se.ORCID http://orcid.org/0000-0002-8181-537X
Jodie P GoodridgeFate Therapeutics, San Diego, CA, USA.
Ebba SohlbergCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-1942-0040
Olli DufvaWellcome Sanger Institute, Wellcome Genome Clymphoid cells (ILCs)ampus, Hinxton, Cambridge, UK.
Sarah A TeichmannWellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-6294-6366
Demi BrownlieCenter for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.ORCID http://orcid.org/0000-0001-5932-6425
Jakob MichaëlssonCenter for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Nicole MarquardtCenter for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet, Huddinge, Sweden.ORCID http://orcid.org/0000-0003-3186-4752
Trevor ClancyOslo Cancer Cluster, NEC OncoImmunity AS, Oslo, Norway.ORCID http://orcid.org/0000-0001-9896-0613
Amir HorowitzDepartment of Immunology & Immunotherapy, Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Karl-Johan MalmbergDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. k.j.malmberg@medisin.uio.no.ORCID http://orcid.org/0000-0002-8718-9373

Funding

Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Harnessing NK cell effector function for immunotherapiesR21AI130760 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOROWITZ, AMIR · 2017 to 2018
$466k
Barncancerfonden (Swedish Childhood Cancer Foundation) PR2020-1059Cancerfonden (Swedish Cancer Society) 21-1793PjCancerfonden (Swedish Cancer Society) 23-2946PjMinistry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2021-073Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2024-053NCI NIH HHS P01 CA111412NIAID NIH HHS R21 AI130760Norges Forskningsråd (Research Council of Norway) 237579Norges Forskningsråd (Research Council of Norway) 275469Vetenskapsrådet (Swedish Research Council) 2021-03069Vetenskapsrådet (Swedish Research Council) 223310
6 · The paper itself

Abstract

The functional diversity of natural killer (NK) cell repertoires stems from differentiation, homeostatic, receptor-ligand interactions and adaptive-like responses to viral infections. In the present study, we generated a single-cell transcriptional reference map of healthy human blood- and tissue-derived NK cells, with temporal resolution and fate-specific expression of gene-regulatory networks defining NK cell differentiation. Transfer learning facilitated incorporation of tumor-infiltrating NK cell transcriptomes (39 datasets, 7 solid tumors, 427 patients) into the reference map to analyze tumor microenvironment (TME)-induced perturbations. Of the six functionally distinct NK cell states identified, a dysfunctional stressed CD56

Indexed as

Killer Cells, NaturalLymphocytes, Tumor-InfiltratingNeoplasmsTranscriptomeTumor MicroenvironmentCD56 AntigenCell DifferentiationGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansSingle-Cell AnalysisCD56 Antigen

Identifiers

PMID38956379
PMCPMC11291284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.